stockrowKrystal Biotech, Inc.
KRYS Healthcare Biotechnology
Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.
- Revenue
- +30.2%
- EPS
- −22.3%
- Free cash flow
- +137.8%
Quarter to September 2026, against a year earlier
Follow KRYS
Alert me
Krystal Biotech, Inc. (KRYS) Return on equity
Krystal Biotech, Inc.'s return on equity over the twelve months to 30 September 2026 was 17.5%, down 1.4 percentage points from fiscal 2025 (18.9%). Over the past ten years it has ranged from −32.8% (fiscal 2017) to 18.9% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 18.9% | 8.57 |
| FY2024 | 10.3% | 8.66 |
| FY2023 | 1.68% | 26.77 |
| FY2022 | −25.1% | (9.38) |
| FY2021 | −15.7% | (2.71) |
| FY2020 | −13.0% | (0.92) |
| FY2019 | −12.1% | 1.31 |
| FY2018 | −13.4% | 19.37 |
| FY2017 | −32.8% | (28.00) |
| FY2016 | −4.76% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| CYTK Cytokinetics, Incorporated compare | 184.7% |
| IBRX ImmunityBio, Inc. compare | 122.9% |
| TGTX TG Therapeutics, Inc. compare | 100.3% |
| KRYS Krystal Biotech, Inc. | 17.5% |
| PTGX Protagonist Therapeutics, Inc. compare | 11.0% |
| CAI Caris Life Sciences,�Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −24.8% |
| TWST Twist Bioscience Corporation compare | −29.6% |
| SYRE Spyre Therapeutics, Inc. compare | −41.2% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on KRYS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement